Cancer Rop Co. Ltd. Market Cap ($121.40 Million)
Market Cap & Net Worth: Cancer Rop Co. Ltd. (180400)
Cancer Rop Co. Ltd. market cap. Cancer Rop Co. Ltd. (KQ:180400) has a market capitalization of $121.40 Million (₩179.14 Billion) as of October 31, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #18275 globally and #799 in its home market, demonstrating a -8.91% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cancer Rop Co. Ltd.'s stock price ₩1820.00 by its total outstanding shares 98428696 (98.43 Million).
Cancer Rop Co. Ltd. Market Cap History (2026–2026)
Cancer Rop Co. Ltd. market cap history from 2026 to 2026. Data shows growth from $121.40 Million to $121.40 Million (0.00% CAGR). Check 180400 live share price for real-time trading data and today's change.
Cancer Rop Co. Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cancer Rop Co. Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see Cancer Rop Co. Ltd. cash conversion from operations for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 180400 by Market Capitalization
Companies near Cancer Rop Co. Ltd. in the global market cap rankings as of October 31, 2026. See Cancer Rop Co. Ltd. net asset quality index to understand what proportion of total assets are financed by equity.
Key companies related to Cancer Rop Co. Ltd. by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #87 globally with a market cap of $224.59 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #143 globally with a market cap of $164.04 Billion USD.
- Natera Inc (NASDAQ:NTRA): Ranked #480 globally with a market cap of $56.33 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #530 globally with a market cap of $51.40 Billion USD ( CN¥351.23 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #87 | Thermo Fisher Scientific Inc | NYSE:TMO | $224.59 Billion | $697.00 |
| #143 | Danaher Corporation | NYSE:DHR | $164.04 Billion | $232.23 |
| #480 | Natera Inc | NASDAQ:NTRA | $56.33 Billion | $414.30 |
| #530 | WuXi AppTec Co Ltd | SHG:603259 | $51.40 Billion | CN¥142.01 |
Market Capitalization of Cancer Rop Co. Ltd. (2026–2026)
Market capitalization of Cancer Rop Co. Ltd. from 2026 to today. Between 2026 and today, Cancer Rop Co. Ltd.'s market cap moved from $121.40 Million to $ 121.40 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩121.40 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Cancer Rop Co. Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $121.40 Million USD |
| MoneyControl | $121.40 Million USD |
| MarketWatch | $121.40 Million USD |
| marketcap.company | $121.40 Million USD |
| Reuters | $121.40 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cancer Rop Co. Ltd.
Dx & Vx Co., Ltd. engages in the development and sale of bio-health care products and provides molecular genetic testing services primarily in South Korea. The company offers healthcare products, including Ofmom Carefree, oat fermented food, and biocleaners; diagnostic products, comprising CLIDEX, precision diagnostics, and in vitro diagnostic kit; health check services; CDx development services;… Read more